Establishing oncological safety of autologous fat transfer for total breast reconstruction: Results from the multicentre BREAST-I and BREAST-II trials.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
total breast reconstruction with AFT between 2015 and 2025
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
These results support the oncological safety of AFT as a reconstructive technique. Future research should include larger cohorts and assess disease-free survival.
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.7%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
[BACKGROUND] Autologous fat transfer (AFT) has gained popularity as a minimally invasive alternative for autologous breast reconstruction post-mastectomy.
- p-value p = 0.025
- 95% CI 95.5-99.7
- 추적기간 8.0 years
APA
van der Venne WBW, Michiels R, et al. (2026). Establishing oncological safety of autologous fat transfer for total breast reconstruction: Results from the multicentre BREAST-I and BREAST-II trials.. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 52(3), 111417. https://doi.org/10.1016/j.ejso.2026.111417
MLA
van der Venne WBW, et al.. "Establishing oncological safety of autologous fat transfer for total breast reconstruction: Results from the multicentre BREAST-I and BREAST-II trials.." European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, vol. 52, no. 3, 2026, pp. 111417.
PMID
41643626 ↗
Abstract 한글 요약
[BACKGROUND] Autologous fat transfer (AFT) has gained popularity as a minimally invasive alternative for autologous breast reconstruction post-mastectomy. It offers aesthetic advantages and improvements in quality-of-life, though concerns persist regarding its oncological safety due to the presence of adipose-derived stem cells (ADSCs).
[METHODS] This pooled follow-up analysis combined data from the multicentre randomised controlled BREAST-I trial and the nonrandomised clinical BREAST-II trial, including women who underwent total breast reconstruction with AFT between 2015 and 2025. The AFT-cohort was compared with a nationwide control group of breast cancer patients derived from the Netherlands Cancer Registry (IKNL), matched by inverse probability weighting. The primary outcome was overall survival (OS). Local and regional recurrences and distant metastases were not included in statistical analyses due to known underreporting in the national registry, but were descriptively assessed within the study cohort.
[RESULTS] A total of 242 AFT-patients and 19936 controls were included. The mean follow-up time was 8.0 years for AFT and 6.9 years for controls. Ten-year crude OS was 97.6 % (95 % CI 95.5-99.7 %) for AFT and 75.7 % (95 % CI 74.7-76.8 %) for controls. After adjustment for confounders and immortal time bias, AFT was not associated with increased mortality (HR 0.34; 95 % CI 0.14-0.88; p = 0.025). Residual confounding and differences in follow-up intensity between cohorts constitute key study limitations.
[CONCLUSIONS] In this pooled multicentre cohort with long-term follow-up, AFT for total breast reconstruction after mastectomy did not negatively affect mortality compared with national registry controls. These results support the oncological safety of AFT as a reconstructive technique. Future research should include larger cohorts and assess disease-free survival.
[METHODS] This pooled follow-up analysis combined data from the multicentre randomised controlled BREAST-I trial and the nonrandomised clinical BREAST-II trial, including women who underwent total breast reconstruction with AFT between 2015 and 2025. The AFT-cohort was compared with a nationwide control group of breast cancer patients derived from the Netherlands Cancer Registry (IKNL), matched by inverse probability weighting. The primary outcome was overall survival (OS). Local and regional recurrences and distant metastases were not included in statistical analyses due to known underreporting in the national registry, but were descriptively assessed within the study cohort.
[RESULTS] A total of 242 AFT-patients and 19936 controls were included. The mean follow-up time was 8.0 years for AFT and 6.9 years for controls. Ten-year crude OS was 97.6 % (95 % CI 95.5-99.7 %) for AFT and 75.7 % (95 % CI 74.7-76.8 %) for controls. After adjustment for confounders and immortal time bias, AFT was not associated with increased mortality (HR 0.34; 95 % CI 0.14-0.88; p = 0.025). Residual confounding and differences in follow-up intensity between cohorts constitute key study limitations.
[CONCLUSIONS] In this pooled multicentre cohort with long-term follow-up, AFT for total breast reconstruction after mastectomy did not negatively affect mortality compared with national registry controls. These results support the oncological safety of AFT as a reconstructive technique. Future research should include larger cohorts and assess disease-free survival.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Female
- Mammaplasty
- Breast Neoplasms
- Middle Aged
- Transplantation
- Autologous
- Adipose Tissue
- Mastectomy
- Adult
- Netherlands
- Aged
- Follow-Up Studies
- Survival Rate
- Registries
- Autologous fat transfer
- Breast cancer
- Breast cancer recurrence
- Distant metastasis
- Fat grafting
- Oncological safety
- Overall survival
- Post-mastectomy breast reconstruction
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.